Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01268098 · ClinicalTrials.gov registry record · Phase 3
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 42
- Enrollment target
NCT01268098 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 42 participants.
The verdict
NCT01268098, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 42 participants
- Enrollment target
Study Summary
Use of PTH (1-84) a recombinant hormone in 25 µg or 50 µg doses for the treatment of adults with hypoparathyroidism. The use of PTH (1-84) should result in a decrease of calcium and vitamin D supplements.
Interventions
- DRUG NPSP558
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2011-02-09 |
| Est. Completion | 2011-11-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01268098
The ClinicalTrials.gov registry entry for NCT01268098 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NPSP558 is the first listed.
NCT01268098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01268098 about?
NCT01268098 is a clinical study titled "Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)". Use of PTH (1-84) a recombinant hormone in 25 µg or 50 µg doses for the treatment of adults with hypoparathyroidism. The use of PTH (1-84) should result in a decrease of calcium and vitamin D supplements.
What is the current status of trial NCT01268098?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 42 participants. The study started on 2011-02-09. Estimated completion is 2011-11-11.
What interventions are being tested in trial NCT01268098?
The interventions under investigation include: NPSP558 (DRUG).
Who is sponsoring clinical trial NCT01268098?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.